Physician profile
John Beary
NPI 1619901055
$9,145.90
in general payments reported to CMS, 2019-2025
21 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $277 · 2021: $1,295 · 2022: $1,756 · 2023: $1,910 · 2024: $1,941 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,427 · Education: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,427.18 |
| Education | $390.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,587.40 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Janssen Biotech, INC. | $1,401.80 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $770.35 | 2020-2025 | Taltz |
| Amgen INC. | $742.15 | 2020-2025 | Otezla, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $572.82 | 2021-2025 | |
| Ucb, INC. | $527.08 | 2021-2025 | Cimzia, Bimzelx |
| Astrazeneca Pharmaceuticals LP | $320.98 | 2021-2025 | Saphnelo |
| Pfizer INC. | $300.57 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $249.07 | 2020-2025 | Orencia |
| Glaxosmithkline, LLC. | $147.79 | 2021-2024 | Benlysta, Nucala |
| Organon LLC | $135.29 | 2024-2025 | Hadlima, Renflexis |
| Sandoz INC. | $70.62 | 2023-2024 | Hyrimoz |
| Sobi, INC | $61.55 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $59.99 | 2025 | Acthar |
| Aurinia Pharma U.S., INC. | $54.57 | 2024-2025 | Lupkynis |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $41.87 | 2025 | |
| Mylan Institutional INC. | $31.44 | 2023 | Hulio |
| Genentech USA, INC. | $21.56 | 2023 | Actemra |
| Biocon Biologics INC | $18.61 | 2023 | Hulio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.38 | 2023 | Cyltezo |
| Horizon Therapeutics Plc | $13.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Beary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.